logo

Merrimack Pharmaceuticals, Inc. (MACK)



Trade MACK now with
  Date
  Headline
4/2/2020 8:44:54 AM Merrimack Divests Early Stage Asset For $2.25 Mln
12/3/2019 8:48:50 AM Merrimack Gets $5 Mln Milestone Payment From Ipsen On Small-cell Lung Cancer Trial; Declares $6.7 Mln Special Dividend
8/26/2019 9:16:50 AM Merrimack Says Current Plan Follows Comprehensive Strategic Review Conducted With Healthcare Financial Advisory Firm
8/22/2019 8:34:13 AM JFL Believes Destruction Of Value And Lack Of Alignment With Stockholders Warrants An Overhaul In Merrimack Boardroom
8/22/2019 8:30:00 AM JFL Capital Issues Letter to Fellow Merrimack Stockholders (Press Release)
5/10/2019 7:38:47 AM Merrimack Pharma Q1 Net Loss $10.5 Mln Or $0.78/Shr Vs Loss $17.8 Mln Or $1.33/Shr Last Year
5/10/2019 7:30:00 AM Merrimack Reports First Quarter 2019 Financial Results (Press Release)
12/10/2018 5:03:07 PM Syneos Health Appoints John Dineen To Board Of Directors
11/7/2018 6:50:13 AM Merrimack Pharma Q3 Loss Per Share $0.30 Vs Loss $0.24 Last Year
10/19/2018 6:13:19 AM Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121 In Patients With Non-Small Cell Lung Cancer Due To Futility
9/6/2018 6:51:02 AM Merrimack Completes Enrollment In Randomized Phase 2 SHERLOC Study Of MM-121 In NSCLC
8/7/2018 6:36:50 AM Merrimack Q2 Net Loss $17.8 Mln Or $1.33 Per Share Vs Net Loss $28.9 Mln Or $2.18 Per Share Last Year
6/25/2018 7:20:50 AM Merrimack Announces Top-Line Results From Randomized Phase 2 Trial Of MM-141 In Front-Line Metastatic Pancreatic Cancer
5/8/2018 6:27:26 AM Merrimack Pharma Q1 Net Loss From Operations $17.8 Mln Or $1.33/Shr Vs Loss $28.7 Mln Or $2.20/Shr Last Year